Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS - Takeaways - MDSpire

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

  • By

  • Rami S. Komrokji

  • Valeria Santini

  • Amer M. Zeidan

  • Mikkael A. Sekeres

  • Pierre Fenaux

  • Azra Raza

  • Moshe Mittelman

  • Sylvain Thépot

  • Rena Buckstein

  • Ulrich Germing

  • Yazan F. Madanat

  • María Díez-Campelo

  • David Valcárcel

  • Anna Jonášová

  • Souria Dougherty

  • Sheetal Shah

  • Qi Xia

  • Libo Sun

  • Shyamala Navada

  • Faye Feller

  • Michael R. Savona

  • Uwe Platzbecker

  • December 31, 2025

  • 0 min

Share

  • 1

    Imetelstat is a telomerase inhibitor showing durable efficacy in treating transfusion-dependent anemia in lower-risk myelodysplastic syndromes.

  • 2

    The Phase III IMerge study led to imetelstat's regulatory approval for patients with LR-MDS who are relapsed, refractory, or ineligible for erythropoiesis-stimulating agents.

  • 3

    Most patients in the study had prior exposure to erythropoiesis-stimulating agents, with varying responses to imetelstat based on previous treatments.

  • 4

    In ESA-ineligible patients, 36% achieved ≥8-week RBC transfusion independence, highlighting imetelstat's potential in this subgroup.

  • 5

    Imetelstat demonstrated limited activity after prior hypomethylating agent therapy, suggesting the need for careful sequencing of treatments in LR-MDS.

Original Source(s)

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

  • by Rami S. Komrokji, Valeria Santini, Amer M. Zeidan, Mikkael A. Sekeres, Pierre Fenaux, Azra Raza, Moshe Mittelman, Sylvain Thépot, Rena Buckstein, Ulrich Germing, Yazan F. Madanat, María Díez-Campelo, David Valcárcel, Anna Jonášová, Souria Dougherty, Sheetal Shah, Qi Xia, Libo Sun, Shyamala Navada, Faye Feller, Michael R. Savona, Uwe Platzbecker

  • December 31, 2025

Related Content

Hematological abnormalities in clinically diagnosed non-alcoholic steatohepatitis: prevalence, clinical correlates, and fibrosis risk in a case–control study from Qatar

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

Approximately 3% to 4% of the population over the age of 50 is diagnosed with monoclonal gammopathy of undetermined significance (MGUS). It carries a lifelong risk of progression to multiple myeloma and lymphoma, requiring risk-adapted monitoring by multidisciplinary teams.

Plasma haem oxygenase-1 and interleukin-6 as adjunct host biomarkers associated with malaria